- Home
- SDGR
SDGR
Schrodinger Inc.
as 02-21-2025 12:42pm EST
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Upcoming Earnings Alert:
Get ready for potential market movements as Schrodinger Inc. SDGR prepares to release earnings report on 26 Feb 2025.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $32.11 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.67 - $33.63 | Next Earning Date: | 02-26-2025 |
| Revenue: | $193,348,000 | Revenue Growth: | -3.03% |
| Revenue Growth (this year): | -4.79% | Revenue Growth (next year): | 31.43% |
Stock Insider Trading Activity of Schrodinger Inc. (SDGR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tran Yvonne | SDGR | EVP, CLO & CPO | Feb 18 '25 | Sell | $28.00 | 3,902 | $109,256.00 | 11,135 | |
| Tran Yvonne | SDGR | EVP, CLO & CPO | Feb 11 '25 | Sell | $24.43 | 828 | $20,228.04 | 11,135 | |
| Herman Jenny | SDGR | SVP & Controller | Feb 11 '25 | Sell | $24.43 | 859 | $20,985.37 | 18,215 |
Latest Schrodinger Inc. News
SDGR Breaking Stock News: Dive into SDGR Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Argus Research
3 days ago
SDGR: Raising target price to $21.00
Insider Monkey
3 days ago
Why Xpeng (XPEV) and Schrodinger (SDGR) Are Advancing Today
Investor's Business Daily
7 days ago
Schrodinger Stock Scores IBD Rating Upgrade
Business Wire
9 days ago
Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26
Argus Research
17 days ago
SDGR: What does Argus have to say about SDGR?
Simply Wall St.
21 days ago
Strong week for Schrödinger (NASDAQ:SDGR) shareholders doesn't alleviate pain of five-year loss
Insider Monkey
23 days ago
Schrödinger (SDGR): Revolutionizing Biopharma with Quantum Mechanics and AI
Compare SDGR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SDGR Schrodinger Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.